Table 4.
Univariate analysis and multivariate analysis of factors affecting the progression-free survival (PFS) of all patients.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| HR (95%Cl) | P value | HR (95%Cl) | P value | |
| Sex | ||||
| male vs female | 0.978 (0.846-1.130) | 0.759 | ||
| Age | ||||
| ≥60 years vs <60 years | 1.013 (0.877-1.171) | 0.862 | ||
| Pathological type | ||||
| adenocarcinoma vs nonadenocarcinoma | 0.923 (0.494-1.723) | 0.801 | ||
| Stage of cancer | ||||
| IIIB vs IV | 0.777 (0.558-1.081) | 0.135 | ||
| Product | ||||
| Bevacizumab biosimilar vs reference Bevacizumab | 1.226 (1.061-1.417) | 0.006 | 1.084 (0.932-1.260) | 0.296 |
| Dose intensity | ||||
| low-dose vs high-dose | 0.995 (0.862-1.149) | 0.946 | ||
| Combined with radiotherapy | ||||
| yes vs no | 0.743 (0.587-0.940) | 0.014 | 0.778 (0.613-0.987) | 0.039* |
| Number of treatment lines | ||||
| 1.000 | 1.000 | 0.000 | 1.000 | 0.001* |
| 2.000 | 1.174 (0.988-1.394) | 1.139 (0.957-1.355) | ||
| ≥3 | 1.485 (1.237-1.7782) | 1.407 (1.168-1.695) | ||
| Combined treatment regimens | ||||
| combined with chemotherapy | 1.000 | 0.000 | 1.000 | 0.000* |
| combined with another targeted therapy | 0.417 (0.617-3.089) | 0.446 (0.284-0.700) | ||
| combined with immunotherapy | 1.381 (0.267-0.519) | 1.260 (0.559-2.841) | ||
| combined with chemotherapy and another targeted therapy | 0.372 (0.267-0.519) | 0.399 (0.295-0.560) | ||
| combined with chemotherapy and immunotherapy | 0.847 (0.686-1.046) | 0.835 (0.673-1.036) | ||
| Combined chemotherapy regimens (if combined) | ||||
| combined with pemetrexed | 1.000 | 0.068 | ||
| combined with taxane | 1.484 (0.876-2.514) | |||
| combined with gemcitabine | 1.497 (0.665-3.368) | |||
| combined with pemetrexed–platinum | 0.983 (0.639-1.512) | |||
| combined with taxane–platinum | 1.200 (0.749-1.920) | |||
| Gene mutation type | ||||
| no genetic mutation | 1.000 | 0.627 | ||
| EGFR exon 18 point mutation | 0.607 (0.195-1.892) | |||
| EGFR exon 19 deletion | 1.089 (0.892-1.330) | |||
| EGFR exon 20 insertion | 0.985 (0.628-1.545) | |||
| EGFR the L858R point mutation | 0.889 (0.735-1.074) | |||
| EGFR double mutation | 1.093 (0.517-2.309) | |||
| ALK rearrangement | 1.025 (0.660-1.592) | |||
| ROS1 rearrangement | 0.308 (0.099-0.961) | |||
| RET rearrangement | 0.723 (0.299-1.749) | |||
| BRAF mutation | 1.226 (0.457-3.287) | |||
| HER2 mutation | 0.662 (0.295-1.483) | |||
| KRAS mutation | 0.856 (0.551-1.329) | |||
| MET aberration | 0.855 (0.354-2.068) | |||
| Brain metastases | ||||
| with vs without | 1.137 (0.958-1.349) | 0.142 | ||
| Liver metastases | ||||
| with vs without | 1.309 (1.077-1.592) | 0.007 | 1.207 (0.990-1.470) | 0.062 |
| History of hypertension | ||||
| with vs without | 1.205 (0.927-1.751) | 0.030 | ||
*p < 0.05.